Physician profile
Stephen Vanna
NPI 1598716623
$8,371.35
in general payments reported to CMS, 2019-2025
52 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,240 · 2020: $2,963 · 2021: $902 · 2022: $222 · 2023: $21.86 · 2024: $22.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $44.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $44.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $830.72 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $707.68 | 2019-2022 | |
| Biogen, INC. | $558.70 | 2019-2021 | |
| Emd Serono, INC. | $524.70 | 2019-2022 | |
| Amgen INC. | $474.39 | 2019-2022 | |
| Ucb, INC. | $455.11 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $441.68 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $384.45 | 2019-2021 | |
| Acorda Therapeutics, INC | $306.88 | 2019-2020 | |
| Lilly USA, LLC | $268.75 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $265.67 | 2019-2021 | |
| Genzyme Corporation | $250.68 | 2019-2022 | |
| Kyowa Kirin, INC. | $245.51 | 2020-2021 | |
| Abbvie INC. | $241.17 | 2019-2022 | |
| Eisai INC. | $217.51 | 2019 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Vanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.